<DOC>
	<DOCNO>NCT02571036</DOCNO>
	<brief_summary>This Phase 1 , open-label , first-in-human ( FIH ) dose-escalation study design evaluate safety , tolerability , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) preliminary antitumor activity DCC-2618 , administer orally ( PO ) , adult patient advanced malignancy . The study consist 2 part , dose-escalation phase expansion phase .</brief_summary>
	<brief_title>A Safety , Tolerability PK Study DCC-2618 Patients With Advanced Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Aggression</mesh_term>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Mastocytosis</mesh_term>
	<mesh_term>Mastocytosis , Systemic</mesh_term>
	<criteria>Patients must meet follow criterion eligible enroll study : 1 . Patients solid tumor hematologic malignancy must histologically confirm , locally advanced malignancy refractory intolerant standard therapy and/or alternative effective therapy available , following exception : GIST patient must progress least imatinib . Systemic mastocytosis patient must confirm diagnosis aggressive systemic mastocytosis ( ASM ) mast cell leukemia ( MCL ) accord 2008 World Health Organization ( WHO ) criteria SM . 2 . Solid tumor hematologic malignancy require archival biopsy sample long cancer therapy administer since sample collect ; otherwise , fresh biopsy require . 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 1 . 4 . The patient , legally authorize representative , capable understand comply protocol sign informed consent document . 5 . Adequate organ function bone marrow reserve indicate follow laboratory assessment perform within 14 day prior first dose study drug : Bone Marrow Function : ANC ≥1500/µL ; hemoglobin ≥9 g/dL ; platelet count ≥75,000/µL . Hepatic Function : Total bilirubin ≤1.5 time upper limit normal ( ULN ) ; aspartate transaminase ( AST ) /alanine transaminase ( ALT ) , ≤3 × ULN ( ≤5 × ULN presence hepatic metastasis ) . Renal Function : Serum creatinine ≤1.5 × ULN creatinine clearance ≥50 mL/min base either urine collection Cockcroft Gault estimation . Coagulation Profile : Prothrombin time ( PT ) international normalize ratio ( INR ) /partial thromboplastin time ( PTT ) ≤1.5 × ULN . Patients stable , maintenance regimen anticoagulant therapy least 30 day prior study drug administration may PT/INR measurement &gt; 1.5 × ULN , opinion Investigator , patient suitable study . An adequate rationale must provide Sponsor prior enrollment . SM patient one inadequate organ function laboratory value may eligible Principal Investigator Sponsor deem disease relate . Patients meet follow criterion exclude study : 1 . Patients leukemias , exception MCL . 2 . Treatment anticancer therapy , include investigational therapy , within 2 week prior administration study drug . For prior therapy halflife longer 3 day , interval must least 28 day prior first administration study drug . 3 . Unresolved toxicity NCI CTCAE Version 4.03 ( i.e. , &gt; Grade 1 baseline ) previous anticancer therapy , exclude alopecia . 4 . The patient know active central nervous system ( CNS ) metastasis . Patients previously treat brain metastasis may participate . 5 . New York Heart Association class III IV heart disease , active ischemia uncontrolled cardiac condition . 6 . Arterial thrombotic embolic event cerebrovascular accident ( include ischemic attack ) , pulmonary embolism , hemoptysis within 6 month start study drug . 7 . Venous thrombotic event ( e.g . deep vein thrombosis ) within 3 month start study drug . 8 . Baseline prolongation ratecorrected QT interval base repeat demonstration QTcF &gt; 450 m male &gt; 470 ms female history long QTc syndrome . 9 . Left ventricular ejection fraction &lt; 50 % low limit normal ( whichever high ) . 10 . Concurrent treatment protonpump inhibitor . 11 . Major surgery within 4 week first dose study drug . 12 . Any clinically significant comorbidities , uncontrolled pulmonary disease , active infection , condition , judgment Investigator , could compromise compliance protocol , interfere interpretation study result , predispose patient safety risk . 13 . Malabsorption syndrome illness could affect oral absorption . 14 . Known human immunodeficiency virus , active hepatitis B , active hepatitis C infection . 15 . If female , patient pregnant lactating . 16 . Known allergy hypersensitivity component investigational drug product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Gastrointestinal stromal tumor ( GIST )</keyword>
	<keyword>systemic mastocytosis ( SM )</keyword>
	<keyword>PDGFR-alpha</keyword>
	<keyword>KIT</keyword>
	<keyword>mast cell leukemia ( MCL )</keyword>
	<keyword>mast cell disease ( MCD )</keyword>
	<keyword>DCC-2618</keyword>
	<keyword>melanoma</keyword>
	<keyword>aggressive systemic mastocytosis ( ASM )</keyword>
</DOC>